CAPS27 – Conference for Asia-Pacific Psychedelic Science

Psychedelic Science is moving fast. Clinical trials are progressing, regulatory frameworks are expanding, and new therapeutic models are being tested in real-world settings. Australia is at the center of this shift. In 2020, Monash University established the country’s first dedicated psychedelic research lab.

In 2023, the Therapeutic Goods Administration created a regulated pathway for authorized psychiatrists to prescribe MDMA and psilocybin, making Australia one of the first countries to formalize clinical access to psychedelic-assisted therapy outside of clinical trials.

Multiple groups across the Asia-Pacific are now conducting world-first and world-class psychedelic research, assessing implementation in real-world clinics, asking questions across a diverse array of disciplines, manufacturing psychedelic compounds in novel ways, shaping novel policy, and developing psychedelic practice.

CAPS27 builds on that foundation. It’s a forum for researchers, clinicians, policymakers, ethicists, cultural scholars, educators, industry leaders, and funders to meet, share evidence, build collaborations, and advance the field together.

Number of Attendees: 700